Cymabay Therapeutics Inc CBAY

NAS: CBAY | ISIN: US23257D1037   21/03/2024
32,48 USD (+0,03%)
(+0,03%)   21/03/2024

21 februari 2024 · The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis · Persbericht

12 februari 2024 · CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis · Persbericht

3 januari 2024 · New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar · Persbericht

15 december 2023 · CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis · Persbericht

7 september 2023 · CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis · Persbericht

10 augustus 2023 · CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase · Persbericht

21 juni 2023 · CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels · Persbericht

7 juni 2023 · CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023 · Persbericht

24 januari 2023 · Thinking about buying stock in Grom Social Enterprises, Intelligent Bio Solutions, Polypid, CymaBay Therapeutics, or Draganfly? · Persbericht

12 maart 2021 · CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021 · Persbericht

Mijn selecties